Investment Summary |
|
---|---|
Date | 2017-09-13 |
Target | Bizagi |
Sector | Software |
Investor(s) | The Invus Group |
Deal Type | Growth Capital |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Private Equity Firm |
---|---|
Founded | 1985 |
PE ASSETS | 10.0B USD |
Size | Mega |
Type | Sector Agnostic |
The Invus Group is a private, global investment firm that makes equity investments in private and public companies. For private companies, Invus seeks control as well as minority investments in high-growth companies where the firm can add strategic value. For public companies, Invus looks to invest in small to mid-cap stocks that are trading below the firm's assessment of their intrinsic business value. Areas of interest include consumer products and services, food, specialty retail, software, biotech, medical devices and products and services to professionals. Invus typically targets investments in the US, Europe, and Asia. The Invus Group was formed in 1985 and is based in New York City.
DEAL STATS | # |
---|---|
Overall | 8 of 9 |
Sector (Software) | 1 of 1 |
Type (Growth Capital) | 2 of 2 |
State (District of Columbia) | 1 of 1 |
Country (United States) | 7 of 8 |
Year (2017) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2016-06-06 |
Ashley Stewart
Secaucus, New Jersey, United States Ashley Stewart is a global lifestyle brand for plus size women’s fashion. Ashley Stewart offers on-trend clothing and accessories through 89 retail stores across the country, a leading social media platform and a rapidly growing e-commerce platform. Ashley Stewart was founded in 1991 and is based in Secaucus, New Jersey. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-03-01 |
Parabilis Medicines
Cambridge, Massachusetts, United States Parabilis Medicines is a biopharmaceutical company with a mission to drastically reduce the burden of disease on patients and their families by inventing new types of drugs that squelch abnormal physiological processes in ways previously imagined but considered unattainable. The company is pioneering the discovery, development and commercialization of Helicon™ peptides, a new drug modality that uniquely combines the cell-permeability and oral dosing optionality of traditional small molecule drugs with the high specificity, broad target accessibility and rapid discovery arc of monoclonal antibody drugs. Parabilis Medicines was founded in 2016 and is based in Cambridge, Massachusetts. |
Buy | - |